Calico's drug, called fosigotifator, is one of a handful run through a clinical trial platform at Massachusetts General Hospital, which disclosed fosigotifator's topline study results Monday.

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint ...

Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on their respective primary endpoints.

Researchers at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital said fosigotifator, the investigational drug being developed by Calico Life Sciences in collaboration with ...

(Cell Reports) Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration ...

The first data have now emerged from a drug Calico developed. It failed. The pill, known as fosigotifator, was not designed to slow aging itself. The Food and Drug Administration does not consider ...

The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a placebo, and therefore ...

The experimental drug, fosigotifator, was tested as a potential treatment for amyotrophic lateral sclerosis (ALS). This deadly neurodegenerative disease affects the nerve cells in the brain and ...